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CD34+ SELECTED AUTOLOGOUS PERIPHERAL BLOOD STEM CELL 
TRANSPLANTATION FOR MULTIPLE SCLEROSIS (MS): REPORT OF 
TOXICITY AND TREATMENT RESULTS AT ONE YEAR OF FOLLOW-UP 
IN 15 PATIENTS 
Calv'e~'as, E.: Saiz, A.; Ma~'i~, P.; Mm'tiJle~, C.; Rovim, M.; 1,7llmn- 
or, N.; Ayme1"icb, M.; Loza,~o, M.; Fe~wa~dez-Az, iles, F.; Urba';zo- 
Ispizzm, A.; Momse*v'at, E.; Gmus, F. BMT Umt, Hospital Cli*~ic, 
Barcelo~a, Spahz. 
Aim: To report he results of a phase II trial to evaluate feasibili- 
ty and toxicity of CD34+ selected antologous peripheral blood 
stem cell transplantation (CD34+/ASCT) and treatment results at 
one year of follow-up. Design and methods. Patients with 
advanced secondary progressive (SP) or relapsing-remitting (RR) 
MS and confirmed worsening of the extended disability status 
scale (EDSS) in the previous year despite interferon or other 
immunotherapies were included. Peripheral blood stem cells were 
obtained by leukaphereses after mobilization with cyclophos- 
phamide (Cy) and G-CSF. CD34+ selection was performed by 
means of Isolex 300 or CliniMACS devices. BCNU, Cy and ATG 
were administered as conditioning reginmn. Results: Fifteen 
patients (9 SPMS and 6 RRMS) with a median EDSS of 6.0 (4.5- 
6.5) and a median of 3 (1-7) relapses in the previous year were 
included. Mobilization was unsuccessful in one patient. During 
mobilization, one patient presented a transient neurologic deterio- 
ration. Main complications during ASCT were engraftment syn- 
drome en three patients, CMV reactivation i one, and two neu- 
rologic deterioration coinciding with high-fever related to ATG. 
Haematological recovery was fast and complete in all cases. At 12 
months, the EDSS improved in three patients, worsened in two 
and remained stable in nine. Despite withdrawal of all immuno- 
suppressive therapy only two patients presented relapses. MRI 
showed disappearance of enhanced T1 lesions but CSF oligoclon- 
al bands persisted in all evaluated cases. Conclusions: 
CD34+/ASCT using BCNU, Cy and ATG as conditioning regi- 
men has an acceptable toxicity" and clearly" reduces the progression 
of the MS. Further follow-up is necessary to establish the real 
impact of the procedure on the long-reran evolution of the disease. 
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IMMUNOABLATIVE THERAPY WITH PURIFIED AUTOLOGOUS STEM 
CELLS RESCUE FOR THE TREATMENT OF POOR PROGNOSIS MS 
Atkil~s, H.L/; Freedmml, 3/I. z, Bozvma~, 3/i. ; Amel, aV.s: Arllo/d, D/; 
Beme-B~vtckler, L 1;Ba'l"-O~; A. ~, CheJz, J. 3; C,bey~ieJ; R.'; Co'/',rhff, R. s; 
D,quette, P?; Halpemly, M.6; H'aebsch, L. l; Lmzeztvi/lc,, p.7; Lapielv'e, 
2:;; JVlessTlev, H.S; O'Comzov, p.4; Sabloff~ [.1; SekL1]3t ' R.r 1. Otta~Lt 
Hospital-Blood and 3/la'J'vozv Tmmplam Progv'aTH, Ottawa, ON, Cmm- 
cla; 2. Ottawa Hospiml-3/IS CliTtic, Ottawa, ON, Cmmda; 3. z]Iom';'eal 
Neztrologie l';,stitme, Morainal, ON, Cmmda; 4. St MichaelS" Hospital, 
Toromo, ON, Carmda; 5. Umvevsitv of Mom;'eal, Montreak ON, 
-GamMa; 6. Stem Cell Lab - Cmmdh71z Blood SeJz&'es', Otta'a~a, ON, 
Cm~ada; 7. McGill UMve~'sity, Momveak ON, C:,mada, 8. UMversity 
Health Network, To';'onto, ON, Cmmda. 
Chronic immune modulation is partially effective in slowing the 
progression of multiple sclerosis (MS). Intensive conditioning reg- 
imens ablate host inmmnity mediating allograft rejection and thus 
should be capable of ablating dysfunctional autoreactive immuni- 
ty. Stringent depletion of inmmne cells in the graft eliminate GvH 
reactions and hematopoietic stem cells (HSC) reconstitute a naive 
graft-derived immune system. As autoimmunity is an acquired 
defect of the imnmne system, purified stem cells t¥om patients 
with autoimmune diseases hould reconstitute an inmmne system 
free of autoreactivity. We are testing these hypotheses in a phase 
II study of 24 MS patients. Patients are chosen on the basis of 
rapid aggressive arly disease and failure to respond to approved 
disease-modifying drugs. Following baseline evaluations and a 
back-up bone marrow harvest, HSC are mobilized using G-CSF, 
Decadron and Cyclophosphamide and collected by leukopheresis. 
Autologous HSC are purified on a CliniMACS. Reinfusion of 
highly purified HSC follows treatment with Busulphan (~I6 
mg/kg dose adjusted to AUC of the first dose), Cyclophosphamide 
(200 mg/kg), and rabbit anti-thymocyte globulin (5 mg/kg). Five 
patients have been treated. Peripheral blood stem ceils (PBSC) 
were mobilized and collected with nominal toxicity. Immune cell 
contamination f the purified HSCs were below the level of detec- 
tion by FACS. The mobilization regimen did not cause worsening 
of MS by clinical or MRI exam. The expected regimen related 
toxicities were minimal following peripheral blood stem cell trans- 
plant. The MS has remained stable in all patients (3-12 months 
post transplan 0. Signs of central nervous ystem inflammation on 
MRI have resolved following treatment. All patients remain pro- 
foundly deficient in T lymphocytes. Although only early follow- 
up is available, complete immune ablation with stem cell rescue 
for MS appears to be well tolerated and no sign of active disease 
can be detected providing preliminary support for role of 
immunoablative therapy in autoimmunity. 
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RE-INFUSED AUTOLOGOUS GRAFT NATURAL KILLER CELLS CORRE- 
LATES WITH ABSOLUTE LYMPHOCYTE COUNT RECOVERY AFTER 
AUTOLOGOUS STEM CELL TRANSPLANTATION: A PILOT STUDY 
Pox'rata, L.F.; Gdstmeal~, D.A.; Pad/ey, D.; BmMy, K.; 3/im-kovic, S.N. 
Mlt~po clime, Roc,%stel; MN. 
Early absolute lymphocyte count (ALC) has been reported to be 
a powerful prognostic indicator of survival after autologous tern 
ceil transplantation (ASCT). One possible source affecting ALC 
recovery includes the re infused autologous graft lymphocytes 
(AGL). To assess if the re-infused AGL correlate with ALC 
recovery post-ASCT, we conducted a pilot study to identify which 
of the re-infused AGL subsets i  most associated with day 15 ALC 
recovery in three patients with multiple myeloma and four 
patients with non-Hodgkin's lymphoma. Using the Spearman 
rank correlation coefficient analysis (r), we compared absolute 
nmnbers of CD3, CD4, CD8, CD19, and CD16+/CD56+/CD3- 
cells/kg of body weight from the apheresis product with ALC 
(cells/ul) at day 15 post-ASCT. The main lymphocyte subsets 
identified in the apheresis product were T cells and NK cells. 
There was no strong correlation between T or B ceils from the 
apheresis product compared with ALC at day 15 post-ASCT 
(CD3, r=0.21; CD4, r=0.32; CD8, r=0.39; and CD19, r-0.14). 
However, there was good correlation between NK cells from the 
apheresis product compared with ALC at day i5 post-ASCT 
(CD16+/CD56+/CD3-, r=0.77). These data provide preliminary 
evidence that the number of re-infused autologous NK cells in the 
apheresis product significantly affect ALC recovery early post- 
ASCT. However, given the small sample size, our results are pri- 
marily hypothesis-generating and subject of further research. 
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PAR~,METERS FOR OPTIMAL TIMING FOR HEMATOPOIETIC PROGEN- 
ITOR CELL COLLECTION 
Kol<, B.; ~7obI~, ~':S.; Loscalzo, J.; Malavade, V.; Bl~ct3l, imh'r, ,4.; 
Baye~; R. Hematology/Omolog 3, North Shorn Umvevsi U Hospital, 
M)Td3nsset, N~'~ 
Controversies exist regarding the timing of leukapheresis for 
peripheral blood progenitor cell (PBPC) collection. Patients are 
often subjected to multiple procedures to collect sufficient nmnber 
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of PBPC. Several European studies had demonstrated a correla- 
tion between precol lect ion CD34+ cells and the nmnber  of 
CD34+ cells collected. However, it is not standard of practice to 
measure preCD34+ counts and base decisions regarding leuka- 
pheresis procedures on these values. In order to investigate the 
most cost effective method and to minimize number of leuka- 
pheresis procedures for optimal PBPC collection, we retrospec- 
tively analyzed data from 42 patients with hematologic malignan- 
cies. Patient diagnoses included nmltiple myeloma, lymphoma nd 
leukemia. Chemotherapy  mobi l izat ion regimens included 
cyclophosphamide, ICE (ifosfamide, carboplatinum and etopo- 
side) and high dose cytarabine and etoposide. G-CSF was given at 
10mcg/kg/day. Several patients were mobilized with growth factor 
alone. Large volume apheresis procedures were done. Three main 
parameters were monitored prior to each apheresis procedure, the 
YVBC, the preCD34+ count and the CD34+ cells collected. There 
was a significant correlation between the preCD34+ count and the 
apheresis CD34+ cell yield. The study indicated that a collection 
of 2.5 X 10 E 6/kg CD34+ cells was obtained in majority of the 
patients if the preCD34+ count was >20/ul. We were unable to 
collect 2.5 X 10 E 6/kg if preCD34 counts were < 5/ul despite 
numerous leukapheresis procedures. If preCD34 counts were 
more than 75-85/ul patients were able to collect 5 X 10 E 6 
CD34+/kg cells in one large volmne procedure. We also noticed a 
weak correlation between the WBC and the preCD34+ count. A 
WBC of 5k/uI or more was noted in most patients who had 
preCD34+ cells of > 10/ul. From our study, we proposed the most 
cost effective method to find the optimal timing for starting PBPC 
collections is to monitor initially with WBC until the count is 
5k/ul. Subsequently, preCD34+ cell count should be used for con- 
tinued monitoring. Leukapheresis i initiated when preCD34+ 
count are > 20/ul in order to collect sufficient CD34+ cells. 
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AUTOLOGOUS BLOOD AND MARROW TRANSPLANTATION (BMT) IN 
OLDER ADULTS (60 YEARS AND OLDER) 
Bm'imz, C. 1; Milh'r, I4/.Ed; 3/lcMillmz, R.2; A~drey, j.s; MeiseTzberg, 
B/; A/lasol~, J.Rd 1. Hematology m~d Medical Omology, Scripps Clinic, 
La ffolla, CA, 2. The Scripps Research Institme, La Jolla, CA; 
3. GreeJzbamn Career Center, BMtimove, ~/ID. 
From April 1994 to July 2002 we performed autologous BMT 
on 82 patients 60 years of age and older for a variety of condi- 
tions. Thirty-six males and 46 females with a median age of 63 
(range 60 to 74) were given a total of 100 transplants. Indica- 
tions for transplant included lymphoma (26), multiple myeloma 
(22), breast cancer (20), acute myelogenous leukemia (7), amy 
loidosis (5), and Hodgkin's disease (2). A variety of preparative 
regimens were employed as shown below. One patient received 
marrow plus peripheral  blood stem cells (PBSC), while 81 
received PBSC only. Priming for mobilization of PBSC includ- 
ed CY plus G CSF and GM-CSF (51), G-CSF alone (20), CY 
plus G-CSF  (I2), VP16 plus G-CSF  (2), and rebound from 
CHOP (i). The median nmnber of days to collect the target 
PBSC was 2 (range 1 to 7). Four patients had to be remobilized 
due to insufficient collection on the first attempt, while 37 
patients required only one day of collection to reach the target. 
A median of 5.21 x i0C'/kg CD34 positive cells (range 1.42 to 
40.57) and 3.80 x 106/kg CD34 positive cells (range 1.40 to 
40.57) were collected and infused, respectively. All patients had 
leukocyte recovery with a median time to ANC > 500 of 10 days 
(range 8 to 16). Recovery of platelets > 50 occurred in 93 trans- 
plants at a median of 18 days (range 12 to 259); in seven trans- 
plants (six pts; three AML, three lymphoma) platelet recovery to 
> 50 did not occur. Fifty-one of 77 evaluable patients (66%) 
achieved a complete response after transplant. Overall survival 
and disease free survival at three years is 44.6% (95% CI 31.6- 
57.6) and 24.2% (95% C1 13.9-34.5), respectively. Forty-five 
patients are alive and only two deaths were attributed to toxici- 
ties related to autologous transplant (VOD - one pt, ARDS - 
one pt). Our experience with transplantation i this group of 
patients has been favorable and no upper age limit has been 
identified. 
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NOVEL HIGH DOSE CHEMOTHERAPY REGIMEN FOR AUTOLOGOUS 
TRANSPLANT IN PATIENTS WITH HODGKIN'S DISEASE 
Gamy 3/lcCo~, A. l; Smith, E.P.I ; Atki1~soJl, 3/1. 3 ; l'Sdd, B.S.1; Baramki, 
B.2; Jztckett, 3d. z; Lo,go, ~.J I. University of Fffisco~sin, MaclisoTz, T'VI; 
2. ~/licldletoJz Memorial Vetemlls Hospita L Madison, HI7; 3. Mic,{,igal~ 
Community Blood Cemers, Grand Rapids, [VII. 
High dose chemotherapy (HDCT)  followed by autologous 
hematopoietic stem cell (HSC) rescue is an accepted treatment for 
relapsed or refractory Hodgkin's Disease (HD). Many patients 
with HD have had prior radiation therapy which precludes the use 
of total body" irradiation (TBI) in the preparative regimen. Multi- 
ple HDCT regimens without TBI have been used, most common- 
ly CBV and BEAM, with reported overall survival (OS) and dis- 
ease free survival (DFS) rates ranging from 30 to 68% and 25 to 
50%, respectively, depending on length of follow-up and disease 
status (chemosensitive or chemorefractory) at transplant. The 
most commonly reported regimen-related to,c i ty (RRT) is inter- 
stitial pneumonitis related to carmustine. At the University of 
Wisconsin Hospital and Clinics (U~VHC) a novel HDCT regi- 
men of thiotepa nd etoposide was developed for use in HD and 
Non-Hodgkin's Lymphoma and consists of thiotepa 300rag/m2 
and etoposide 700rag/m2 given consecutively on days -6, -5, and - 
4. Since 1987, f i fty-three patients with HD have undergone 
HDCT and autologous HSC rescue utilizing this reginren. Medi- 
an age was 33 years, and the majority of patients (89%) had nodu- 
lar sclerosing HD. At the time of transplant 9 (I7%) patients were 
in complete remission, 30 (57%) patients were in partial remis- 
sion, and 11 (21%) patients were refractory to salvage therapy. 
Eight ( i5%) were considered primary induction failures, and 6 
(11%) were in second or third relapse. Three patients were in 
untreated relapse. Response to induction therapy was < I2 months 
in 32 (60%) patients. With a median follow-up of 45.7 months, 
five year OS is 59% (95%CI, 35-82%), and DFS is 36% (95%CI, 
4-67%). The most common RRT was reversible gastrointestinal 
toxicity. Grade III stomatitis occurred in 60%. There was no 
grade IV stomatitis. Other grade III toxicities included febrile 
neutropenia (98%), thrombosis (7%), and electrolyte abnormali- 
ties (16.7%). One patient died before day +100 due to progressive 
HD, but there were no deaths due to RRT. Two patients have 
developed secondary myelodysplasia. No cases of interstitial pneu- 
monitis occurred, and no patients developed VOD. In conclusion, 
thiotepa and etoposide is a novel HDCT regimen for use in 
patients with relapsed or refractory HD which offers low RRT 
and equivalent long-term OS and DFS compared to other report- 
ed HDCT regimens. 
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THE IMPACT OF STEM CELL TRANSPLANTATION ON MANTLE CELL 
LYMPHOMA 
LogsdoTz, 3l.Sd; Greet, ff.p.1; Goodma,, S.A.t; Vztsivikala, M. 1; 
HamiltoJ~, K.2; SchueJlillg, F.Gd; ffagasia, M.H.S; Movgmz, D.Sd; 
IGTssim, A.s; Stein, R.SJ; l~IcCurley, T.L. 2 1. T'~nderbilt - [Iematol- 
ogy/Oncology, Nashville, TN, 2. Vamlert, ih Pathology, Nashville, TN. 
Background: Variable r sults with autologous and allogeneic 
stem cell transplantation for mantle ceil lymphoma have been 
reported by single institutions. Methods: We analyzed ata on 23 
patients who underwent a total of 24 peripheral blood stem cell 
and bone marrow transplants at Vanderbilt University Hospital 
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